Nanovibronix Inc Stock Price, News & Analysis

NanoVibronix (NASDAQ: NAOV) has secured U.S. Patent No. 12,409,105 B2 through its subsidiary ENvue Medical Holdings LLC. The patent, titled "Insertion Device Positioning Guidance System and Method," protects the company's proprietary electromagnetic positioning technology for guiding medical devices like feeding tubes.

The technology aims to enhance real-time visualization and accuracy during medical procedures, reducing misplacement risks and improving clinical safety. CEO Doron Besser emphasized that this patent strengthens their intellectual property portfolio and reinforces their market position in navigation and guidance systems for enteral feeding applications.

NanoVibronix (NASDAQ: NAOV) has announced that its subsidiary ENvue Medical has been granted U.S. Patent No. 12,402,953 B2 for its innovative real-time imaging overlay technology in navigation systems. The patent, issued on September 2, 2025, protects ENvue's proprietary method of overlaying electromagnetic navigation data directly onto various medical imaging platforms including X-ray, CT, ultrasound, and MRI.

The technology enhances feeding tube and catheter placement procedures by enabling clinicians to visualize the device's path in real-time on medical images, potentially reducing misplacement risks and improving workflow efficiency. CEO Doron Besser highlighted that this patent strengthens the company's position in the feeding tube placement market while creating opportunities for expansion into vascular navigation.

NanoVibronix (NASDAQ: NAOV), a medical technology company, has announced a 1-for-10 reverse stock split effective August 11, 2025, at 4:05 p.m. ET. The company's common stock will begin trading on a split-adjusted basis on August 12, 2025, under the same NASDAQ symbol NAOV.

The reverse split will reduce outstanding shares from 7,968,868 to approximately 796,887. The action follows stockholder approval granted on July 17, 2025, which authorized the Board to implement a split ratio between 1-for-2 and 1-for-50. Proportional adjustments will be made to equity awards, warrants, and other convertible securities. Stockholders will have fractional shares rounded up to the nearest whole number.

NanoVibronix (NASDAQ: NAOV), a medical technology company, has secured a significant private placement financing of up to $50 million through convertible preferred stock. The deal includes an initial closing of $8 million and a second closing of $2 million through Series H Convertible Preferred Stock, with an initial conversion price of $1.01 per share.

The agreement also provides the institutional investor with rights to purchase up to an additional $44 million in preferred stock over 36 months. The company plans to use $5 million from the initial proceeds to redeem outstanding Series X Preferred Stock, with the remainder allocated for working capital. Palladium Capital Group is serving as the exclusive placement agent for this transaction.

NanoVibronix (NASDAQ: NAOV) has announced the development of ENvue Drive™, an intelligent robotic platform designed to automate electromagnetic navigation for enteral and vascular access procedures at the bedside. The platform aims to address a $10+ billion market opportunity by integrating with the company's FDA-cleared electromagnetic guidance technology.

The system targets the growing enteral feeding devices market (projected to reach $3.99 billion by 2030) and vascular access device market (expected to exceed $10.5 billion by 2030). Currently in preclinical development, ENvue Drive aims to reduce the need for multiple clinicians during procedures while maintaining precision and safety. The company expects to have a functional prototype by year-end and plans to initiate regulatory submissions later this year.

NanoVibronix (NASDAQ: NAOV) has secured an agreement with an upstate New York hospital to provide two ENvue™ Navigation Systems for enteral feeding tube placement. The FDA-cleared systems, expected for delivery in Q3 2025, utilize electromagnetic technology for real-time visualization during tube placement.

The agreement marks ENvue's first formal system adoption in the northeastern U.S., following recent commercial activity in the southeast. The company recently received a U.S. patent for electromagnetic navigation in pediatric feeding, supporting its broader product development strategy.

NanoVibronix's ENvue Medical division has secured U.S. Patent No. 12,324,632 for its pediatric feeding tube guidance system. The patented technology uses electromagnetic tracking for real-time feeding tube placement visualization, reducing reliance on X-rays. The system targets a significant U.S. market opportunity exceeding $150 million annually, serving approximately 400,000 preterm infants and additional pediatric patients requiring feeding tube placement, totaling over 1.5 million procedures yearly. Currently FDA-cleared for adult use only, ENvue Medical is preparing to pursue FDA 510(k) clearance for pediatric applications. The patent strengthens the company's intellectual property portfolio and demonstrates its commitment to innovation in feeding tube placement technologies.

NanoVibronix announced the immediate retirement of CEO Brian Murphy, who will remain as a director on the Board. Doron Besser, CEO of ENvue Medical Holdings (a subsidiary acquired by NanoVibronix in February 2025), has been appointed as the new CEO. The leadership transition follows NanoVibronix's strategic acquisition of ENvue, a company specializing in enteral feeding solutions. The merger aimed to combine strengths and create synergies in the medical device market. Chairman Christopher Fashek praised Murphy's contributions in driving product innovation and expanding distribution. Besser expressed optimism about capitalizing on new market opportunities and enhancing the product portfolio post-merger. The company remains focused on commercializing existing technologies while developing innovative medical solutions.

NanoVibronix (NASDAQ: NAOV) has issued an official statement denying false information circulated by Flash Alert and FintelAlerts regarding a purported $26 million registered direct offering of common stock. The alleged offering was falsely reported to be priced at $0.45 under Nasdaq rules. The company explicitly stated that it has not priced and is not consummating any registered direct offering. NanoVibronix is actively investigating this misinformation and plans to take necessary actions to protect its stockholders and reputation.